|
Variable
|
Placebo (n = 17)
|
Linagliptin (n = 14)
|
P
|
|---|
|
Age (years), mean ± SD
|
63 ± 6
|
61 ± 5
|
0.21
|
|
Sex female, n %
|
10 (59%)
|
3 (21%)
|
0.04
|
|
Race
|
0.49
|
|
BL
|
12 (71%)
|
8 (57%)
|
|
Wh
|
4 (24%)
|
3 (21%)
|
|
Other
|
1 (6%)
|
3 (21%)
|
|
Medications
|
|
Metformin
|
14 (82%)
|
12 (86%)
|
0.99
|
|
Insulin
|
6 (35%)
|
5 (36%)
|
0.99
|
|
BP
|
|
Systolic
|
133 ± 18
|
128 ± 10
|
0.30
|
|
Diastolic
|
77 ± 7
|
81 ± 7
|
0.23
|
|
BMI
|
30.6 ± 2.9
|
31.2 ± 4.4
|
0.67
|
|
Percent fat
|
38 ± 10
|
30 ± 10
|
0.04
|
|
Waist cm
|
105 ± 8
|
107 ± 17
|
0.22
|
|
Basic metabolic rate
|
1476 ± 448
|
1868 ± 293
|
0.02
|
|
Fasting glucose
|
130 ± 44
|
125 ± 26
|
0.70
|
|
Serum creatinine
|
0.9 ± 0.3
|
1.1 ± 0.4
|
0.24
|
|
eGFR
|
84 ± 19
|
83 ± 21
|
0.85
|
|
Cholesterol
|
168 ± 53
|
166 ± 52
|
0.92
|
|
HbA1c
|
7.4 ± 1.0
|
7.1 ± 0.7
|
0.50
|
